Thermo Fisher Scientific Inc TMO

What the company does

Thermo Fisher Scientific Inc is a mega-cap company in the Healthcare sector (Diagnostics & Research), with a market value of $249.1B, based in the USA.

It employs about 125,000 people and has been listed since Jan 13, 1978.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 35.5 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 9% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 23.9 — they expect higher earnings.

The average analyst price target is 750.92, 11% above the current price (their view, not ours).

The stock sits at 88% of its one-year range (0% = the low, 100% = the high).

The risks

• No risk flags were detected from the data we have.

Strengths

• ✅ Profitable — 14 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Buys back its shares (2% fewer shares in a year).
• ✅ Most analysts rate it buy (23 vs 1).
• ✅ Pays a dividend (0.1% a year).

What changed this week

Over the past week the stock fell 2.3% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

It set a new one-year high this week.

The company published its quarterly report this week — see the plain-language summary above.

This week's news

• Thermo Fisher Scientific (TMO) Benefits on Broad-Based Recovery Across Life-Science Markets finance.yahoo.com · 2026-10-23
  What the article says

  Broyhill Asset Management, a Charlotte-based firm, issued its third-quarter 2026 investor letter. The letter can be downloaded here. The Broyhill Equity Composite decreased by 0.3% in Q3, underperforming the MSCI All Country World Index, which gained 1.7%. For the first nine months of the year, the Composite returned… source ↗

• Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo A 354-page report profiles 36 companies, including Abbott, bioMérieux, Roche and Thermo Fisher, across respiratory, gastrointestinal and meningitis testing in 15 countries — though costs and shifting disease prevalence complicate the outlook Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Clinical Laboratory… source ↗

• NGS Kits Market Forecasts Growth from $6.84 Billion (2025) to $19.36 Billion by 2036, Profiling Illumina, Thermo Fisher Scientific, Roche, Oxford Nanopore & 11 Other Key Players finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo 201-Page Report Finds Library Preparation Leads and Long-Read Sequencing Grows Fastest as Clinical Oncology Testing and Genomics Programs Expand, While Fragmented Reimbursement and Lab Capacity Limits Slow Adoption Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "NGS Kits Market: Focus on Workflow, Sequencing… source ↗

• IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth? finance.yahoo.com · 2026-10-22
  What the article says

  Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics - US's Substack. In this article, we will summarize the bulls' thesis on IDXX. IDEXX Laboratories, Inc.'s share was trading at $553.48 as of October 21st 2026. IDXX's trailing and forward P/E were 36.65 and 31.45… source ↗

• Global Peptide Synthesis Market Forecast to 2031: Size, Share, Trends, and Growth | GLP-1 Boom Lifts Demand for Peptide Synthesis finance.yahoo.com · 2026-10-22
  What the article says

  Company Logo The global peptide synthesis market is projected to grow from $0.98 billion in 2026 to $1.54 billion by 2031, a new report finds, as GLP-1 drugs and expanding peptide pipelines drive demand for custom synthesis; Thermo Fisher, Merck KGaA, GenScript and Bachem are among 30 companies profiled. Dublin, Oct.… source ↗

• Company News for Oct 22, 2026 finance.yahoo.com · 2026-10-22
  What the article says

  Capital One Financial Corp.'s (COF) shares gained 2.5% after the company reported third-quarter 2026 adjusted earnings of $6.69 per share, surpassing the Zacks Consensus Estimate of $5.45 per share. Shares of Bank OZK (OZK) surged 4.2% after the company posted third-quarter 2026 adjusted earnings of $1.50 per share,… source ↗

What changed since last week

• Risk flag cleared: earnings report coming up.

• The average analyst target moved from 683.84 to 750.92.

• A new quarterly report was published (quarter ended Sep 30, 2026).